ACTR-42. PI3K/mTOR PATHWAY ACTIVATION SELECTED PHASE II STUDY OF EVEROLIMUS (RAD001) WITH AND WITHOUT TEMOZOLOMIDE IN THE TREATMENT OF ADULT PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMA [NCT NCT02023905]

Functional activation of the PI3K/AKT/mTOR pathway is seen in ~50% of low-grade gliomas and correlates with worse survival. Everolimus is a selective inhibitor of mTOR that targets mTOR-raptor signaling, halting proliferation and indirectly inhibiting angiogenesis. This phase 2 study evaluated the e...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Taylor, Jennie, Molinaro, Annette, Rodriguez Almaraz, Eduardo, Downey, Ciara, Phillips, Joanna, Ann Oberheim-Bush, Nancy, Butowski, Nicholas, Chang, Susan, Berger, Mitchel, Prados, Michael, Haas-Kogan, Daphne, Clarke, Jennifer
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2019
Soggetti:
Adult Clinical Trials - Non-Immunologic
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846978/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.084
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi